Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for ESC-R Enterobacteriaceae in pediatrics
NCT02543866Phase 1Recruiting
- Sponsor
- Seattle Children's
- Start
- Feb 2017
- Primary completion
- Sep 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fecal microbiome transplant in Enterobacteriaceae infection, sponsored by Seattle Children's. Primary endpoint: Incidence, severity, and relatedness of solicited, unsolicited, and serious adverse events at 12 months. Started Feb 2017; status: recruiting.
02
Drugs
fecal microbiome transplant
03
Conditions
Enterobacteriaceae infection
Beyond the preview
Go deeper on NCT02543866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543866.